CYTEK BIOSCIENCES, INC. (CTKB) Operating Margin
- Operating margin · 12 months: Value -21.60%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -21.60% | Operating income / revenue. Period ending 2026-06-30. $-44.65M ÷ $206.71M × 100 ≈ -21.60% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -44.65M USD | Operating Income (Loss) |
| Revenue | 206.71M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 96.68M USD | Cost of Goods and Services Sold |
| Research and development | 37.26M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-44.65M | $206.71M | $96.68M | $37.26M | (m) | -21.60% |
| 2026-03-31 | $-43.87M | $204.17M | $98.61M | $36.35M | (m) | -21.49% |
| 2025-12-31 | $-40.38M | $201.49M | $97.03M | $36.47M | (m) | -20.04% |
| 2025-09-30 | $-31.80M | $196.83M | $91.60M | $37.23M | (m) | -16.16% |
| 2025-06-30 | $-26.86M | $196.03M | $89.35M | $38.16M | (m) | -13.70% |
| 2025-03-31 | $-24.76M | $197.05M | $88.80M | $39.33M | (m) | -12.57% |
| 2024-12-31 | $-20.52M | $200.45M | $89.35M | $39.40M | (m) | -10.24% |
| 2024-09-30 | $-23.65M | $201.21M | $90.71M | $40.55M | (m) | -11.75% |
| 2024-06-30 | $-25.82M | $197.71M | $89.04M | $41.84M | (m) | -13.06% |
| 2024-03-31 | $-26.42M | $200.79M | $89.39M | $43.97M | (m) | -13.16% |
| 2023-12-31 | $-27.84M | $193.01M | $83.59M | $44.15M | (m) | -14.43% |
| 2023-09-30 | $-27.62M | $183.12M | $77.37M | $43.03M | (m) | -15.09% |
| 2023-06-30 | $-19.84M | $175.59M | $70.16M | $40.51M | (m) | -11.30% |
| 2023-03-31 | $-11.61M | $166.06M | $64.22M | $36.81M | (m) | -6.99% |
| 2022-12-31 | $-1.80M | $164.04M | $63.06M | $34.86M | (m) | -1.10% |
| 2022-09-30 | $-571.00K | $154.59M | $59.36M | $32.19M | (m) | -0.37% |
| 2022-06-30 | $10.85M | $148.49M | $58.84M | $29.61M | (m) | 7.31% |
| 2022-03-31 | $5.67M | $138.74M | $53.91M | $27.37M | (m) | 4.09% |
| 2021-12-31 | $9.16M | $127.95M | $48.81M | $24.44M | (m) | 7.16% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $13.66M | $92.84M | $41.13M | $13.69M | (m) | 14.71% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |